DEAL - SPAC - de-SPAC
Luxembourg, 10 December 2021 –
Arendt advised Alvotech Holdings S.A. (“Alvotech”), a fully integrated specialty biopharmaceutical group focused on the development and manufacturing of high quality biosimilar medicines, on all Luxembourg law aspects of the agreement to enter into a business combination (de-SPACing) with Oaktree Acquisition Corp. II, a SPAC sponsored by an affiliate of Oaktree Capital Management, L.P., and on all Luxembourg law aspects of structuring the business combination.
The combined group is expected to have an implied initial enterprise value of approximately USD 2.25 billion, and will enable further investment in the Alvotech platform and portfolio, furthering the company’s mission of bringing cost-effective biosimilars to patients in all major markets around the globe.
With unparalleled expertise in SPACs and de-SPACing transactions in Luxembourg, Arendt is optimally positioned to advise on the structuring, set-up, listing and subsequent business combination of SPACs in Luxembourg.
Arendt team involved: